The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering

  • Data: 10 Dic 2019
Comorbosità mediche

Abstract

  • Proprotein convertase subtilisin/kexin type 9 inhibitors reduce risk for major adverse cardiac events.
  • There is debate about efficacy in patients with low-density lipoprotein cholesterol <100 mg/dL.
  • Longer trials are needed to adequately address this question.

Studio

J Clin Lipidol. 2018 Sep - Oct;12(5):1102-1105. doi: 10.1016/j.jacl.2018.05.016. Epub 2018 Jun 1

Autori

Maki KC

SISDCA

La SISDCA è una società scientifica no-profit a componente multidisciplinare: medici di differenti specializzazioni,  psicologi, dietisti, infermieri, tecnici della riabilitazione, educatori sanitari ed operatori della nutrizione.

CONTATTI